BRIEF-REGENXBIO Announces Completion Of Pivotal Enrollment And Initiates Commercial Production In Duchenne Gene Therapy Program

Reuters10-30

Oct 30 (Reuters) - Regenxbio Inc RGNX.O:

REGENXBIO ANNOUNCES COMPLETION OF PIVOTAL ENROLLMENT AND INITIATES COMMERCIAL PRODUCTION IN DUCHENNE GENE THERAPY PROGRAM
REGENXBIO INC - TOPLINE PIVOTAL DATA EXPECTED EARLY Q2 2026, BLA SUBMISSION MID-2026

Source text: ID:nPn4091Rra

Further company coverage: RGNX.O

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2579117747?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 19:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579117747","market":"fut","top_or_hot":-1,"title":"BRIEF-REGENXBIO Announces Completion Of Pivotal Enrollment And Initiates Commercial Production In Duchenne Gene Therapy Program","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-REGENXBIO Announces Completion Of Pivotal Enrollment And Initiates Commercial Production In Duchenne Gene Therapy Program</title></head><body><p><span>Oct 30 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/RGNX\">Regenxbio Inc</a> <span>RGNX.O</span>:</p><ul><li><p>REGENXBIO ANNOUNCES COMPLETION OF PIVOTAL ENROLLMENT AND INITIATES COMMERCIAL PRODUCTION IN DUCHENNE GENE THERAPY PROGRAM</p></li><li><p>REGENXBIO INC - TOPLINE PIVOTAL DATA EXPECTED EARLY <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026, BLA SUBMISSION MID-2026</p></li></ul><p>Source text: <span>ID:nPn4091Rra</span></p><p>Further company coverage: <span>RGNX.O</span></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-REGENXBIO Announces Completion Of Pivotal Enrollment And Initiates Commercial Production In Duchenne Gene Therapy Program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-REGENXBIO Announces Completion Of Pivotal Enrollment And Initiates Commercial Production In Duchenne Gene Therapy Program\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-30 19:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-REGENXBIO Announces Completion Of Pivotal Enrollment And Initiates Commercial Production In Duchenne Gene Therapy Program</title></head><body><p><span>Oct 30 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/RGNX\">Regenxbio Inc</a> <span>RGNX.O</span>:</p><ul><li><p>REGENXBIO ANNOUNCES COMPLETION OF PIVOTAL ENROLLMENT AND INITIATES COMMERCIAL PRODUCTION IN DUCHENNE GENE THERAPY PROGRAM</p></li><li><p>REGENXBIO INC - TOPLINE PIVOTAL DATA EXPECTED EARLY <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026, BLA SUBMISSION MID-2026</p></li></ul><p>Source text: <span>ID:nPn4091Rra</span></p><p>Further company coverage: <span>RGNX.O</span></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nTUA50PLVH:1","article_id":"2579117747","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579117747","pubTimestamp":1761822472,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-REGENXBIO Announces Completion Of Pivotal Enrollment And Initiates Commercial Production In Duchenne Gene Therapy ProgramOct 30 (Reuters) - Regenxbio Inc RGNX.O:REGENXBIO ANNOUNCES COMPLETION OF","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","RGNX":"Regenxbio Inc","BK4139":"生物科技","BK4563":"昨日强势股"},"translate_title":"简介-REGENXBIO宣布完成Duchenne基因治疗项目的关键入组并启动商业生产","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RGNX":0.9},"content_text":"BRIEF-REGENXBIO Announces Completion Of Pivotal Enrollment And Initiates Commercial Production In Duchenne Gene Therapy ProgramOct 30 (Reuters) - Regenxbio Inc RGNX.O:REGENXBIO ANNOUNCES COMPLETION OF PIVOTAL ENROLLMENT AND INITIATES COMMERCIAL PRODUCTION IN DUCHENNE GENE THERAPY PROGRAMREGENXBIO INC - TOPLINE PIVOTAL DATA EXPECTED EARLY Q2 2026, BLA SUBMISSION MID-2026Source text: ID:nPn4091RraFurther company coverage: RGNX.O","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2579117747","isCrawlerRequest":true}